Table 2.
Treatment-related adverse events in 74 patients with small-cell lung cancer
Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | |
---|---|---|---|---|
Acute kidney injury | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
Alanine aminotransferase increased | 2 (3%) | 1 (1%) | 1 (1%) | 0 (0%) |
Amylase increased | 2 (3%) | 1 (1%) | 0 (0%) | 0 (0%) |
Anaemia | 7 (9%) | 2 (3%) | 0 (0%) | 0 (0%) |
Arthralgia | 8 (11%) | 1 (1%) | 0 (0%) | 0 (0%) |
Aspartate aminotransferase increased | 5 (7%) | 1 (1%) | 1 (1%) | 0 (0%) |
Asthenia | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) |
Blood alkaline phosphatase increased | 3 (4%) | 1 (1%) | 0 (0%) | 0 (0%) |
Cardiac tamponade | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) |
Conjunctivitis | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Decreased appetite | 12 (16%) | 0 (0%) | 0 (0%) | 0 (0%) |
Dermatitis acneiform | 3 (4%) | 1 (1%) | 0 (0%) | 0 (0%) |
Dyspnoea | 6 (8%) | 2 (3%) | 0 (0%) | 0 (0%) |
Electrocardiogram ST segment elevation | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Erythema | 10 (14%) | 0 (0%) | 0 (0%) | 0 (0%) |
Erythema multiforme | 5 (7%) | 1 (1%) | 0 (0%) | 0 (0%) |
Fatigue | 23 (31%) | 3 (4%) | 0 (0%) | 0 (0%) |
Hypoalbuminaemia | 13 (18%) | 0 (0%) | 0 (0%) | 0 (0%) |
Hypotension | 1 (1%) | 2 (3%) | 1 (1%) | 0 (0%) |
Hypoxia | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Infection | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) |
Lipase increased | 1 (1%) | 2 (3%) | 3 (4%) | 0 (0%) |
Liver function test abnormal | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) |
Maculopapular rash | 10 (14%) | 2 (3%) | 0 (0%) | 0 (0%) |
Nausea | 14 (19%) | 0 (0%) | 0 (0%) | 0 (0%) |
Neutrophil count decreased | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Palmar-plantar erythrodysaesthesia syndrome | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) |
Pancytopenia | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) |
Pericardial effusion | 7 (9%) | 0 (0%) | 2 (3%) | 0 (0%) |
Peripheral oedema | 18 (24%) | 2 (3%) | 0 (0%) | 0 (0%) |
Photophobia | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Photosensitivity reaction | 7 (9%) | 1 (1%) | 0 (0%) | 0 (0%) |
Platelet count decreased | 2 (3%) | 1 (1%) | 0 (0%) | 0 (0%) |
Pleural effusion | 17 (23%) | 6 (8%) | 0 (0%) | 0 (0%) |
Pulmonary oedema | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Thrombocytopenia | 4 (5%) | 3 (4%) | 5 (7%) | 0 (0%) |
Troponin increased | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Tumour haemorrhage | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
Vomiting | 10 (14%) | 0 (0%) | 0 (0%) | 0 (0%) |
White blood cell count decreased | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
Data are number of patients (%). The table shows grade 1–2 treatment-related adverse events in ≥10% of patients in any treatment cohort and all grade 3–5 adverse events. All-cause adverse events and serious adverse events are shown in the appendix (pp 11–25).